The Elder Care Market: Products and Services

  • January 2014
  • -
  • BCC Research
  • -
  • 172 pages

STUDY GOALS AND OBJECTIVES

The aim of this report is to provide an in-depth analysis and forecast of the pharmaceutical, housing and assistive device segments of the U.S. eldercare market. The report will focus on the size of the U.S. market, with comparisons to other markets in developed countries in Europe and Asia.
Demographic implications, funding implications for both individuals and countries, products and services currently available in the housing and assistive device markets, and research regarding future pharmaceutical treatments will be discussed. Future pharmaceutical treatments will concentrate on the areas of concern for individuals who are older than 65, including:
• Heart disease/stroke.
• Cancer treatments.
• Kidney disease medications
• Diabetes medications.
• Arthritis prescription medications.
• Osteoporosis medications.
• Pain medications.
• Neurological health medications (e.g., dementia, depression).
• Respiratory medications and products.

REASONS FOR DOING THE STUDY

Individuals born between 1946 and 1964 (commonly referred to as baby boomers) will have a profound effect on the structure of societies as well as the services and products offered by governments and manufacturers. This huge market of active, relatively wealthy and demanding individuals will place enormous stress on governments to provide services and on businesses to provide appropriate products. Outlining the impact of this generation and investigating current and future products and opportunities for well-positioned companies are the primary focuses of this report.

SCOPE OF REPORT

This report offers forecasts by product segment (i.e., pharmaceuticals, housing and assistive devices, and technology) from 2013 through 2018, including supporting analyses for projections.
Report segments include a demographic background of the market in the U.S. and worldwide, healthcare products and services, housing services and needs, and assistive technologies for the eldercare market. International markets are discussed and information is provided on industry structure.
Profiles of leading companies involved in the eldercare pharmaceutical, housing and assistive device industries are provided. Information on company placement within the designated market and strategic analyses of the company’s available and emerging products is discussed.

INTENDED AUDIENCE

This report provides a broad background on the structure of the U.S. eldercare healthcare market and the chief issues it faces. It offers the information needed to understand the current market and to address the emerging one. Comparisons with the eldercare market in Europe, Asia and developing countries are provided.
This is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, investor consultants and others interested in the eldercare market, its products, participants and future.

INFORMATION SOURCES

Information for this report was obtained from industry participants; the Center for Medicare and Medicaid Services (CMS), National Institutes of Health (NIH), National Institutes on Aging, Agency on Health Care Policy and Research, the Centers for Disease Control (CDC), U.S. Census Bureau and other U.S. government agencies; The World Health Organization (WHO); the American Hospital Association, Alzheimer’s Association, American Heart Association; The Gerontological Society of America, American Lung Association, American Medical Association, American Association of Retired Persons, Assisted Living Federation of America (ALFA); the Pew Charitable Trusts, Kaiser Family Foundation; Robert Wood Johnson Foundation and MetLife Mature Markets; industry experts; literature searches; company annual reports and 10Ks; and product literature.
All data collected were analyzed by BCC Research personnel to determine specific findings and to project markets. When precise information is not available, a consensus was made using reasonable assumptions and estimates based on historical data.

ANALYST CREDENTIALS

Peggy S. Lehr is the market research analyst of this report. Ms. Lehr holds a BS in Journalism from the University of Colorado, Boulder, and a MS in Communication from the University of Denver. Ms. Lehr has been involved with the medical/nursing industry for more than 25 years. Recent reports for BCC Research include nine healthcare reports and her latest report, HLC078B: Magnetic Resonance Imaging: The Global Market, which was published in September 2013.

REPORT HIGHLIGHTS

The U.S. eldercare market reached $286.7 billion in 2012. This market is expected to grow from $319.8 billion in 2013 to $436.6 billion by 2018, with a compound annual growth rate (CAGR) of 6.4% for the five-year period, 2013 to 2018.
This report provides:
• An in-depth analysis and forecast of the eldercare market.
• Analyses of market trends, with data from 2012, estimates for 2013, and projections of CAGRs for the period 2013 and 2018.
• Identification of the U.S. and worldwide markets by demographics.
• Discussion on international markets, as well as information on the industry's structure.
• A breakdown of the overall market into segments that include healthcare products and services, housing services and needs, and assistive technologies.

Table Of Contents

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2

STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THE STUDY 2
SCOPE OF REPORT 2
INTENDED AUDIENCE 3
INFORMATION SOURCES 3
ANALYST CREDENTIALS 3
RELATED BCC RESEARCH REPORTS 4
BCC RESEARCH ONLINE SERVICES 4
DISCLAIMER 4

CHAPTER 2 SUMMARY 6

EMPHASIS OF THE REPORT 6
HEALTHCARE 6
HOUSING 7
ASSISTIVE TECHNOLOGY 7
SUMMARY TABLE PROJECTED NEEDS OF THE U.S. ELDERLY, THROUGH 2018 ($
MILLIONS) 8
SUMMARY FIGURE PROJECTED NEEDS OF THE ELDERLY BY TYPE OF NEED, 2013
AND 2018 (%) 9

CHAPTER 3 OVERVIEW OF GLOBAL ELDERLY POPULATION 11

DEFINITIONS 11
TRENDS IN GLOBAL AGING 11
HEALTHCARE AND AGING 11
HOUSING AND AGING 12
THE GLOBAL ENVIRONMENT FOR THE ELDERLY 12
GLOBAL SOCIAL ENVIRONMENT 12
Intergenerational Living Issues in Developing Countries 13
Intergenerational Living Issues in Developed Countries 13
GLOBAL HOUSING REALITY FOR THE ELDERLY 13
Europe 13
China 13
GLOBAL ECONOMIC REALITY FOR THE ELDERLY 14
Economic Trends for Elderly Outside the U.S. 14
Europe 14
India 14
Japan 15
Economic Trends for U.S. Elderly 15
GLOBAL DEMOGRAPHIC TRENDS, BY COUNTRY 15
TABLE 1 PERCENT OF POPULATION AGE 65 AND OLDER IN SELECTED COUNTRIES,
2012 (MILLIONS/%) 15
THE ELDERLY IN THE U.S. 16
DEMOGRAPHICS IN THE U.S. 16
TABLE 2 ELDERLY POPULATIONS COMPARED WITH OVERALL POPULATIONS BY
STATE, 2009 16
TABLE 3 U.S. ELDERLY POPULATION, BY STATE, AS A PERCENTAGE OF THE
OVERALL STATE POPULATION, 2010 (%) 18
HEALTH OF THE U.S. ELDERLY 19
U.S. Health Trends 19
Discrepancies in Minority Health Status 19
Elderly Living with Chronic Health Conditions 20
SHIFTING DEMOGRAPHICS IN THE U.S. 20
Racial and Ethnic Changes 20
FIGURE 1 U.S. POPULATION OVER 65 BY RACE, 2010 (%) 20
GOVERNMENT LEGISLATION AND PROGRAMS AIMED AT THE ELDERLY 21
THE AMERICANS WITH DISABILITIES ACT 21
ADA and Employee Rights 22
THE TELECOMMUNICATIONS ACT OF 1934 22
THE FAIR HOUSING ACT 22
AIR CARRIER ACCESS ACT 23
VOTING ACCESSIBILITY FOR THE ELDERLY AND HANDICAPPED ACT OF
1984 23
ARCHITECTURAL BARRIERS ACT OF 1968 23
MEDICAL DEVICE LEGISLATION 23
THE AMERICAN RECOVERY AND REINVESTMENT ACT OF 2009 24
U.S. GOVERNMENT SPONSORED NUTRITION PROGRAMS 24
NON-GOVERNMENTAL NUTRITION PROGRAMS 24
END-OF-LIFE CONSIDERATIONS 25
LEGAL MATTERS 25

CHAPTER 4 INDUSTRY TRENDS BY SECTOR-HEALTHCARE 27

U.S. HEALTHCARE FOR THE ELDERLY 27
TABLE 4 PROJECTED U.S. MARKET FOR ELDERCARE HEALTHCARE MEDICATIONS,
PRODUCTS AND SURGICAL PROCEDURES, THROUGH 2018 ($ MILLIONS) 28
HOSPITALIZATIONS FOR HEALTHCARE PROBLEMS OF THE ELDERLY 28
TABLE 5 NUMBER OF DISCHARGES FROM NONFEDERAL U.S. HOSPITALS FOR
INDIVIDUALS 65 OR OLDER, 2010 (THOUSANDS) 28
ARTHRITIS 29
CURRENT TREATMENTS 29
Medications 29
Rheumatoid Arthritis 30
COX2 Inhibitor 30
Disease-modifying Antirheumatic Drugs 30
Biologics to Treat RA 30
Corticosteroids 31
NSAIDs 31
Osteoarthritis 31
THE FUTURE BURDEN OF ARTHRITIS IN THE U.S. 31
FIGURE 2 FUTURE BURDEN OF ARTHRITIS FOR THOSE OVER 65 IN THE U.S. BY
GENDER, 2010-2030 ($ MILLIONS) 31
ARTHRITIS TREATMENT MARKET PROJECTIONS 32
TABLE 6 PROJECTED U.S. MARKET FOR PRESCRIPTION ARTHRITIS MEDICATIONS
FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 33
CARDIOVASCULAR DISEASES 33
CARDIOVASCULAR DISEASE IN THE U.S. 33
Risk Factors 34
Current Treatments for Heart Disease 34
TABLE 7 SELECTED LISTING OF HEART DISEASE MEDICATIONS BY BRAND NAME
AND MANUFACTURER 35
Surgical Options 37
CARDIOVASCULAR TREATMENT MARKET ANALYSIS 37
TABLE 8 U.S. MARKET FOR CARDIOVASCULAR DISEASE MEDICATIONS AND
SURGERY, THROUGH 2018 ($ MILLIONS) 38
TABLE 9 PROJECTED U.S. MARKET FOR CARDIOVASCULAR DRUGS AND SURGERY
FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 38
CANCER 38
TYPES OF CANCER 39
GLOBAL RISK FACTORS 39
FIGURE 3 ESTIMATED NEW CASES OF CANCER, GLOBALLY, 2008 (%) 39
CANCER RATES IN THE U.S. ELDERLY 40
CANCER TREATMENT MARKET ANALYSIS 41
TABLE 10 LEADING CANCER DRUGS, WITH PRODUCT, MANUFACTURER AND
INDICATION, 2012 41
MARKET ANALYSIS FOR U.S. CANCER DRUGS 42
TABLE 11 PROJECTED U.S. MARKET FOR CANCER TREATMENT DRUGS, THROUGH
2018 ($ MILLIONS) 42
TABLE 12 PROJECTED MARKET FOR CANCER DRUGS FOR U.S. ELDERLY PATIENTS,
THROUGH 2018 ($ MILLIONS) 42
DIABETES 43
TYPE 2 DIABETES INTERNATIONALLY 43
Type 2 Diabetes in Asia 43
PREVALENCE OF TYPE 2 DIABETES IN THE U.S. 44
TABLE 13 PREVALENCE OF DIABETES IN THE U.S., THROUGH 2018 (CASES IN
MILLIONS) 44
CURRENT TREATMENT OF DIABETES 44
TYPE 1 DIABETES 44
Insulin 44
Insulin Administration Devices 45
TYPE 2 DIABETES 45
Sulfonylureas 45
TABLE 14 SULFONYLUREAS 46
Biguanides 46
Alpha-Glucosidase Inhibitor 46
Glitazones 47
Prandial Glucose Regulators 47
GLP-1 Analogs/Incretin Mimetics 47
Amylin Mimetic 47
TABLE 15 ORAL HYPOGYCEMICS 48
MONITORING DEVICES FOR DIABETES 48
DIABETES THERAPY MARKET LEADERS 49
DIABETES MARKET ANALYSIS 49
TABLE 16 PROJECTED U.S. MARKET FOR ORAL DIABETES MEDICATIONS AND
MONITORING PRODUCTS, THROUGH 2018 ($ MILLIONS) 49
TABLE 17 PROJECTED U.S. MARKET FOR ORAL DIABETES MEDICATIONS AND
MONITORING PRODUCTS FOR THE ELDERLY, THROUGH 2018 ($ MILLIONS) 50
SENSORY IMPAIRMENTS 50
TABLE 18 PROJECTED U.S. MARKET FOR SENSORY IMPAIRMENT PHARMACEUTICALS,
SURGERY AND PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2018 ($
MILLIONS)
50
SPEECH IMPAIRMENT 51
WRITING DIFFICULTY 51
VISION IMPAIRMENT 51
TABLE 19 ESTIMATED NUMBER OF CASES BY VISION PROBLEM FOR INDIVIDUALS
OVER 40, 2010 52
Macular Degeneration 52
TABLE 20 PROJECTED GLOBAL MARKET FOR PRODUCTS TO TREAT AMD, THROUGH
2018 ($ MILLIONS) 53
TABLE 21 PROJECTED U.S. MARKET FOR PRODUCTS TO TREAT AMD FOR
INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 53
Cataracts 53
TABLE 22 PROJECTED COSTS OF CATARACT SURGERY FOR THE U.S. ELDERLY,
THROUGH 2018 ($ MILLIONS) 54
Glaucoma 54
Ethnic Disparities 54
Glaucoma Prescription Market 55
TABLE 23 PROJECTED U.S. ELDERLY MARKET FOR GLAUCOMA PRESCRIPTION
MEDICATIONS, THROUGH 2018 ($ MILLIONS) 55
Eyewear 55
TABLE 24 PROJECTED U.S. EYEWEAR SALES, THROUGH 2018 ($ MILLIONS) 56
Market for Eyewear Products for Seniors 56
TABLE 25 PROJECTED U.S. MARKET FOR EYEWEAR FOR INDIVIDUALS OVER 65,
THROUGH 2018 ($ MILLIONS) 56
HEARING IMPAIRMENT 57
Causes of Hearing Loss 57
Market Analysis for Hearing Aid Products 57
TABLE 26 PROJECTED U.S. MARKET FOR HEARING AID PRODUCTS, THROUGH 2018
($ MILLIONS) 58
TABLE 27 PROJECTED U.S. MARKET FOR HEARING AID PRODUCTS FOR THE
ELDERLY, THROUGH 2018 ($ MILLIONS) 58
NEUROLOGICAL DISEASES 58
TABLE 28 PROJECTED MARKET IN THE U.S. FOR DEMENTIA AND DEPRESSION
MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 59
ALZHEIMER'S DISEASE 59
FIGURE 4 CAUSES OF DEMENTIA IN INDIVIDUALS OVER 65 (%) 60
Economic Burden 60
Current Treatments for Alzheimer's 61
TABLE 29 COMMON PRESCRIPTION MEDICATIONS FOR ALZHEIMER'S DISEASE,
2013 62
Market Analysis for Dementia Costs 62
TABLE 30 PROJECTED MARKET IN THE U.S. FOR DEMENTIA MEDICATIONS FOR
INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 63
DEPRESSION 63
Origins of the Disease 63
Genetic Factors 63
Biological Factors 64
Sociological Factors 64
Psychological Factors 64
Costs of Depression 64
Market Analysis for Depression in the Elderly 65
TABLE 31 PROJECTED U.S. MARKET FOR DEPRESSION MEDICATIONS FOR THE
ELDERLY, THROUGH 2018 ($ MILLIONS) 65
ORTHOPEDIC 65
TABLE 32 PROJECTED U.S. MARKET FOR ORTHOPEDIC MEDICATIONS AND
SURGERIES FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 66
OSTEOPOROSIS 66
TABLE 33 UNCONTROLLABLE AND CONTROLLABLE RISK FACTORS FOR
OSTEOPOROSIS 66
Osteoporosis Medications 67
TABLE 34 OSTEOPOROSIS MEDICATIONS BY TYPE 67
Market Analysis for Osteoporosis Medications 67
TABLE 35 PROJECTED U.S. MARKET FOR OSTEOPOROSIS MEDICATIONS, THROUGH
2018 ($ MILLIONS) 68
TABLE 36 PROJECTED U.S. MARKET FOR OSTEOPOROSIS MEDICATIONS FOR
INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 68
FALLS AND THE ELDERLY 68
JOINT REPLACEMENT 68
Market Analysis 69
TABLE 37 PROJECTED U.S. COST OF SELECTED ORTHOPEDIC SURGERY, THROUGH
2018 ($ MILLIONS) 69
TABLE 38 PROJECTED U.S. COST OF SELECTED ORTHOPEDIC SURGERY FOR
INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 70
Market Leaders 70
FIGURE 5 MARKET LEADERS FOR RECONSTRUCTIVE IMPLANT PRODUCTS (%) 70
RESPIRATORY 71
TABLE 39 PROJECTED U.S. MARKET FOR RESPIRATORY MEDICATIONS AND
PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 71
ALLERGIES 72
Current Treatments for Allergies 72
TABLE 40 CURRENT ALLERGY TREATMENTS 73
Allergy Market Analysis 74
TABLE 41 PROJECTED MARKET FOR PRESCRIPTION ALLERGY MEDICATIONS IN THE
U.S., THROUGH 2018 ($ MILLIONS) 74
TABLE 42 PROJECTED U.S. MARKET FOR PRESCRIPTION ALLERGY MEDICATIONS
FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 75
ASTHMA 75
Treatments 76
TABLE 43 PROJECTED U.S. MARKET FOR ASTHMA MEDICATIONS FOR INDIVIDUALS
OVER 65, THROUGH 2018 ($ MILLIONS) 76
COPD 76
TABLE 44 PROJECTED U.S. MARKET FOR COPD MEDICATIONS FOR INDIVIDUALS
OVER 65, THROUGH 2018 ($ MILLIONS) 77
COPD Treatment Options 77
TABLE 45 CURRENT TREATMENT OPTIONS FOR ASTHMA/COPD IN U.S. 78
Emphysema 79
Chronic Bronchitis 79
OXYGEN THERAPY 79
TABLE 46 PROJECTED U.S. MARKET FOR HOME OXYGEN AND RESPIRATORY
SUPPLIES FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 80
LOSS OF PATENT PROTECTION 80
TABLE 47 MAJOR ASTHMA/COPD DRUGS LOSING PATENT PROTECTION BETWEEN
2008-2021 80
OTHER CHRONIC CONDITIONS 81
DENTAL HEALTH 81
UROLOGICAL PROBLEMS 81
Incontinence Medications 81
TABLE 48 PROJECTED U.S. MARKET FOR INCONTINENCE MEDICATIONS FOR
INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 82
BENIGN PROSTATIC HYPERPLASIA (BPH) 82
TABLE 49 SELECTED MEDICATIONS FOR BPH 82
TABLE 50 PROJECTED U.S. MARKET FOR BPH MEDICATIONS FOR INDIVIDUALS
OVER 65, THROUGH 2018 ($ MILLIONS) 83
OBESITY 83

CHAPTER 5 INDUSTRY TRENDS BY SECTOR-HOUSING 85

UNPAID CAREGIVERS 85
TOLL ON CAREGIVERS 85
LONG-TERM CARE 86
FIGURE 6 PROJECTED LIFETIME LONG-TERM CARE NEEDS FOR INDIVIDUALS OVER
65 (%) 86
U.S. HOUSING FOR ELDERLY 87
MARKET ANALYSIS 87
TABLE 51 PROJECTED U.S. MARKET FOR SENIOR HOUSING AND DAY SERVICES FOR
INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 88
AT-HOME REMODELING 88
TABLE 52 PROJECTED U.S. MARKET FOR HOME REMODELING FOR INDIVIDUALS
OVER 65, THROUGH 2018 ($ MILLIONS) 89
HOME HEALTHCARE SERVICES 89
TABLE 53 PROJECTED U.S. MARKET FOR HOME HEALTH SERVICES FOR
INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 89
ADULT DAY CENTERS 90
TABLE 54 PROJECTED U.S. MARKET FOR ADULT DAY CARE SERVICES FOR
INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 91
COMPETITIVE LANDSCAPE FOR HOME HEALTHCARE SERVICES 91
HOUSING FOR LOWER INCOME INDIVIDUALS 91
INSTITUTIONAL CARE ALTERNATIVES FOR SENIORS 92
DEMOGRAPHICS OF INDIVIDUALS IN INSTITUTIONAL SETTINGS 92
ASSISTED LIVING, SKILLED NURSING, MEMORY CARE PROVIDERS 93
TABLE 55 PROJECTED U.S. MARKET FOR SENIOR ASSISTED LIVING AND SKILLED
NURSING FACILITIES FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 93
TOP INDUSTRY PROVIDERS 93
TABLE 56 TOP 10 ASSISTED LIVING PROVIDERS IN U.S. BY CAPACITY, 2012 94
FIGURE 7 PERCENT RANKING OF ASSISTED LIVING PROVIDERS BY CAPACITY IN THE
U.S., 2012 (%) 94
TABLE 57 TOP 10 INDEPENDENT LIVING PROVIDERS BY CAPACITY, 2012 95
FIGURE 8 PERCENT RANKING OF INDEPENDENT LIVING PROVIDERS BY CAPACITY IN
THE U.S., 2012 (%) 96
TABLE 58 TOP FIVE MEMORY CARE LIVING PROVIDERS IN THE U.S., 2012 97
ASSISTED LIVING 97
NURSING HOMES 97
MEMORY CARE 98
MARKET CONSTRAINTS 98
RESTRICTED SUPPLY OF NURSING BEDS 98
COST CONTAINMENT EFFORTS BY GOVERNMENT PAYERS 99
IMPLICATIONS OF THE AFFORDABLE CARE ACT (ACA) 99
Care Coordination 99
REIMBURSEMENT ISSUES 100
Medicaid Reimbursement 100
LACK OF FINANCIAL RESOURCES BY SENIORS 100
INDUSTRY COMPETITION 100
RETAINING COMPETENT STAFF 101
CREDIT AND MODERNIZATION FOR SKILLED NURSING FACILITIES 101
INDEPENDENT LIVING 101
ACTIVE ADULT COMMUNITIES 102
RECREATIONALLY BASED RETIREMENT COMMUNITIES 102
SENIOR HOUSING MARKET OPPORTUNITIES 103
MEMORY CARE FACILITIES 103
HOME HEALTHCARE 103
U.S. REGIONAL ANALYSIS 103
NEW FACILITY CONSTRUCTION 103
ACQUISITIONS AND MERGERS IN THE ELDERCARE HOUSING INDUSTRY 103
TABLE 59 SELECTED ACQUISITIONS AND MERGERS IN THE ELDERCARE MARKET,
2011 TO 2013 ($ MILLIONS) 104

CHAPTER 6 INDUSTRY TRENDS, BY SECTOR-ASSISTIVE TECHNOLOGIES 106

PROJECTED ASSISTIVE TECHNOLOGIES MARKET ANALYSIS FOR ELDERS 106
TABLE 60 PROJECTED U.S. ASSISTIVE TECHNOLOGY MARKET FOR INDIVIDUALS
OVER 65, THROUGH 2018 ($ MILLIONS) 106
FIGURE 9 PROJECTED U.S. MARKET FOR ASSISTIVE TECHNOLOGY FOR INDIVIDUALS
OVER 65, 2013 AND 2018 (%) 107
MEDICAL AND PERSONAL MONITORING AIDS 108
ACTIVITY LOCATION/PERSONAL MONITORING AIDS 108
Activity/Emergency Location Monitors 108
Remote Medical Monitors 108
Market Fragmentation 109
TABLE 61 SELECTED MEDICAL/PERSONAL MONITORING AID MANUFACTURERS 109
MEDICAL/PERSONAL MONITORING AIDS MARKET GROWTH 109
TABLE 62 PROJECTED U.S. SALES OF MEDICAL/PERSONAL MONITORING AIDS FOR
INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 110
MARKET DRIVERS FOR MEDICAL AND PERSONAL MONITORING AIDS 110
ACCESS AIDS 110
HOME ELEVATORS 110
WHEELCHAIR LIFTS 110
STAIR CLIMBERS 111
ACCESSIBLE BATHS AND SHOWERS 111
TRANSFER LIFTS 111
DOOR OPENERS 111
ACCESS AIDS MANUFACTURERS 111
TABLE 63 ACCESS AIDS MANUFACTURERS 112
DAILY LIVING AIDS 112
TABLE 64 SELECTED MANUFACTURERS OF DAILY LIVING AIDS 113
PROJECTED MARKET FOR DAILY LIVING AIDS FOR SENIORS 113
TABLE 65 PROJECTED MARKET FOR DAILY LIVING AIDS FOR SENIORS, THROUGH
2018 ($ MILLIONS) 113
MOBILITY AIDS 114
TABLE 66 PROJECTED U.S. MARKET FOR MOBILITY PRODUCTS FOR INDIVIDUALS
OVER 65, THROUGH 2018 ($ MILLIONS) 114
WHEELCHAIRS, SCOOTERS AND ACCESSORIES 114
Wheelchairs 114
TABLE 67 WHEELCHAIR MANUFACTURERS 115
Scooters 116
TABLE 68 SCOOTER MANUFACTURERS 116
AMBULATORY AIDS 116
TABLE 69 PROJECTED U.S. MARKET FOR AMBULATORY AIDS FOR INDIVIDUALS
OVER 65, THROUGH 2018 ($ MILLIONS) 117
TABLE 70 AMBULATORY AID MANUFACTURERS 117
MOTOR VEHICLE MODIFICATIONS 117
TABLE 71 PROJECTED U.S. MARKET FOR MOTOR VEHICLE MODIFICATIONS FOR
INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 118
TABLE 72 VEHICLE ASSESS CONVERSION KIT MANUFACTURERS 118
NAVIGATION AIDS 118
TABLE 73 PROJECTED U.S. MARKET FOR NAVIGATION AIDS FOR INDIVIDUALS OVER
65, THROUGH 2018 ($ MILLIONS) 119
OTHER AIDS 119
TABLE 74 PROJECTED U.S. MARKET FOR OTHER AIDS FOR INDIVIDUALS OVER 65,
THROUGH 2018 ($ MILLIONS) 119
BEDS 120
ERGONOMIC AIDS 120
COMMUNICATION AIDS 120
TABLE 75 PROJECTED U.S. ELDERLY MARKET FOR COMMUNICATION AIDS,
THROUGH 2018 ($ MILLIONS) 120
Speech Aids 121
Writing Aids/Computer Access 121
Input Devices 121
Output Devices 121
Software Products 121
Telephony Accessories 122
Text Telephones 122
Amplified Telephones 122
Vision/Reading Aids 122

CHAPTER 7 DEVELOPMENTAL PIPELINE FOR ELDERCARE PHARMACEUTICALS 124

TABLE 76 MEDICINES IN DEVELOPMENT FOR SELECTED THERAPEUTIC AREAS,
2012 124
CANCER 124
BREAST 124
TABLE 77 MAJOR PRODUCT PIPELINES FOR BREAST CANCER 125
COLORECTAL CANCER 125
TABLE 78 MAJOR PRODUCT PIPELINES FOR COLORECTAL CANCER 126
DIABETES 126
TABLE 79 MAJOR PRODUCT PIPELINES FOR DIABETES 126
HEART DISEASE/STROKE 128
TABLE 80 MAJOR PRODUCT PIPELINES FOR HEART DISEASE/STROKE 128
KIDNEY DISEASE 128
TABLE 81 MAJOR PRODUCT PIPELINES FOR KIDNEY DISEASE 128
MUSCULOSKELETAL 129
OSTEOARTHRITIS 129
TABLE 82 MAJOR PRODUCT PIPELINES FOR OSTEOARTHRITIS 129
OSTEOPOROSIS 129
TABLE 83 MAJOR PRODUCT PIPELINES FOR OSTEOPOROSIS 129
Pain 130
TABLE 84 MAJOR PRODUCT PIPELINES FOR PAIN 130
Rheumatoid Arthritis 130
TABLE 85 MAJOR PRODUCT PIPELINES FOR RHEUMATOID ARTHRITIS 131
NEUROLOGICAL 131
DEPRESSION PRODUCT PIPELINE 131
TABLE 86 MAJOR PRODUCT PIPELINES FOR DEPRESSION 132
DEMENTIA PRODUCT PIPELINE 132
TABLE 87 MAJOR PRODUCT PIPELINE FOR DEMENTIA PHARMACEUTICALS 133
RESPIRATORY 133
ASTHMA 133
TABLE 88 MAJOR PRODUCT PIPELINES FOR ASTHMA 133
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 134
TABLE 89 MAJOR PRODUCT PIPELINES FOR COPD 134

CHAPTER 8 COMPANY DIRECTORY 136

PHARMACEUTICALS 136
ABBOTT LABORATORIES 136
Business Overview 136
Products 136
ASTRAZENECA PLC 137
Business Overview 137
Products 137
BRISTOL-MYERS SQUIBB 137
Business Overview 137
Products 137
CENTOCOR 138
Business Overview 138
Products 138
COVIDIEN 138
Business Overview 138
Products 138
DJO GLOBAL, INC. 138
Business Overview 139
Products 139
ELI LILLY 139
Business Overview 139
Products 139
ENDO PHARMACEUTICALS, INC. 139
Business Overview 139
Products 140
FOREST PHARMACEUTICALS 140
Business Overview 140
Products 140
GLAXOSMITHKLINE PLC 140
Business Overview 140
Products 140
JANSSEN PHARMACEUTICALS, INC. 141
Business Overview 141
Products 141
JOHNSON and JOHNSON 141
Business Overview 141
Products 141
MERCK 142
Business Overview 142
Products 142
NOVARTIS INTERNATIONAL AG 142
Business Overview 142
Products 142
NOVO NORDISK 143
Business Overview 143
Products 143
PFIZER 143
Business Overview 143
Products 143
PURDUE PHARMACEUTICALS LP 144
Business Overview 144
Products 144
ROCHE PHARMACEUTICALS 144
Business Overview 144
Products 144
SANOFI-AVENTIS 145
Business Overview 145
Products 145
SERVIER LABORATORIES, LTD 145
Business Overview 145
Products 145
TAKEDA PHARMACUETICALS 146
Business Overview 146
Products 146
VECTURA GROUP PLC 146
Business Overview 146
MEDICAL DEVICES 146
BOSTON SCIENTIFIC 146
Business Overview 147
Products 147
MEDTRONIC, INC. 147
Business Overview 147
Products 147
ST. JUDE MEDICAL, INC. 147
Business Overview 148
Products 148
HOUSING OPTIONS 148
ASSISTED LIVING CONCEPTS, LLC 148
Business Overview 148
Products 148
BROOKDALE SENIOR LIVING 148
Business Overview 149
Products 149
CAPITAL SENIOR LIVING CORP. 149
Business Overview 149
Products 149
EMERITUS CORP. 149
Business Overview 150
Products 150
FIVE STAR QUALITY CARE, INC. 150
Business Overview 150
Products 150
LIFE CARE CENTERS OF AMERICA 150
Business Overview 150
Products 150
LIVHOME, INC. 151
Business Overview 151
Products 151
HCR MANOR CARE 151
Business Overview 151
Products 151
SUNRISE SENIOR LIVING, INC. 151
Business Overview 152
Products 152
ASSISTIVE DEVICES 152
AandD MEDICAL/LIFESOURCE 152
Business Overview 152
Products 152
ALIMED INC. 152
Business Overview 152
Products 153
ALLIED HEALTHCARE PRODUCTS, INC. 153
Business Overview 153
Products 153
AMERICAN MEDICAL ALERT CORP. 153
Business Overview 153
Products 153
ANALOGIC INC. 154
Business Overview 154
Products 154
BAXTER INTERNATIONAL, INC. 154
Business Overview 154
Products 154
BAYER AG (MILES-BAYER) 155
Business Overview 155
Products 155
BLUE CHIP MEDICAL PRODUCTS 155
Business Overview 155
Products 155
BRUNO INDEPENDENT LIVING AIDS INC. 155
Business Overview 156
Products 156
CARD GUARD AG 156
Business Overview 156
Products 156
CARETRENDS 156
Business Overview 156
Products 157
COBOLT SYSTEMS LTD. 157
Business Overview 157
Products 157
DOLPHIN COMPUTER ACCESS LTD. 157
Business Overview 157
Products 158
DUXBURY SYSTEMS INC. 158
Business Overview 158
Products 158
ECHO THERAPEUTICS 158
Business Overview 158
Products 158
EXACT DYNAMICS B.V. 159
Business Overview 159
Products 159
FREEDOM SCIENTIFIC INC. 159
Business Overview 159
Products 159
FRESENIUS MEDICAL CARE AG and CO. KGAA 160
Business Overview 160
Products 160
GRAHAM-FIELD HEALTH PRODUCTS 160
Business Overview 160
Products 160
GW MICRO INC. 160
Business Overview 161
Products 161
HEALTH FRONTIER, INC. 161
Business Overview 161
Products 161
HONEYWELL HOMMED 161
Business Overview 161
Products 162
HUMANWARE 162
Business Overview 162
Products 162
INCLINATOR COMPANY OF AMERICA 162
Business Overview 162
Products 162
INVACARE CORP. 163
Business Overview 163
Products 163
JOHNSON and JOHNSON 163
Business Overview 163
Products 163
KIMBERLY CLARK 163
Business Overview 164
Products 164
KROWN MANUFACTURING 164
Business Overview 164
Products 164
LIFE ALERT EMERGENCY RESPONSE 164
Business Overview 164
Products 164
LIFE GUARDIAN LLC 165
Business Overview 165
Products 165
LIFESCAN, INC. 165
Business Overview 165
Products 165
LIFTAVATOR INC. 165
Business Overview 166
Products 166
MEDLINE INDUSTRIES INC. 166
Business Overview 166
Products 166
MEDTRONIC MINIMED 166
Business Overview 166
Products 166
NIPRO DIAGNOSTICS INC. 167
Business Overview 167
Products 167
NXSTAGE MEDICAL, INC. 167
Business Overview 167
Products 167
OBS MEDICAL 167
Business Overview 168
Products 168
OMRON HEALTHCARE, INC. 168
Business Overview 168
Products 168
OPTELEC 168
Business Overview 169
Products 169
OTTO BOCK HEALTHCARE GMBH 169
Business Overview 169
Products 169
PARI PHARMA 169
Business Overview 169
Products 170
PHILIPS LIFELINE SYSTEMS INC. 170
Business Overview 170
Products 170
PRIDE MOBILITY PRODUCTS CORP. 170
Business Overview 170
Products 170
PULSE METRIC INC. 171
Business Overview 171
Products 171
RESMED, INC. 171
Business Overview 171
Products 171
ROCHE DIAGNOSTICS 171
Business Overview 172
Products 172
SAVARIA CORP. 172
Business Overview 172
Products 172
SCOTTCARE CORP. 172
Business Overview 172
Products 173
SIEMENS HEARING INSTRUMENTS INC. 173
Business Overview 173
Products 173
STARKEY LABORATORIES 173
Business Overview 173
Products 173
SUNRISE MEDICAL INC. 174
Business Overview 174
Products 174
SVENSKA CELLULOSA AKTIEBOLAGET SCA 174
Business Overview 174
Products 174
THORNDIKE PRESS 174
Business Overview 175
Products 175
THYSSENKRUPP ACCESS 175
Business Overview 175
Products 175
TYCO INTERNATIONAL 175
Business Overview 175
Products 175
WIDEX 176
Business Overview 176
Products 176
REHABILITATION 176
DJO GLOBAL, INC. 176
Business Overview 176
Products 176
KINDRED HEALTHCARE 177
Business Overview 177
Products 177

CHAPTER 9 GLOSSARY 179

ACTIVITIES OF DAILY LIVING (ADLS) 179
ALZHEIMER'S DISEASE 179
ARTHRITIS 179
ASSISTED LIVING 179
ASSISTIVE TECHNOLOGY 179
BABY BOOMER 180
CARDIOVASCULAR DISEASE 180
CAREGIVERS 180
CONGESTIVE OBSTRUCTIVE PULMONARY DISEASE (COPD) 180
DEMENTIA 180
DIABETES 180
DURABLE MEDICAL EQUIPMENT 181
ELDER/SENIOR 181
GERONTOLOGY 181
HOSPICE CARE 181
INSTRUMENTAL ACTIVITIES OF DAILY LIVING (IADL) 181
LONG-TERM CARE 181
PROSTHETICS AND ORTHOTICS 181



LIST OF TABLES

SUMMARY TABLE PROJECTED NEEDS OF THE U.S. ELDERLY, THROUGH 2018 ($
MILLIONS) 8
TABLE 1 PERCENT OF POPULATION AGE 65 AND OLDER IN SELECTED COUNTRIES,
2012 (MILLIONS/%) 15
TABLE 2 ELDERLY POPULATIONS COMPARED WITH OVERALL POPULATIONS BY
STATE, 2009 16
TABLE 3 U.S. ELDERLY POPULATION, BY STATE, AS A PERCENTAGE OF THE OVERALL
STATE POPULATION, 2010 (%) 18
TABLE 4 PROJECTED U.S. MARKET FOR ELDERCARE HEALTHCARE MEDICATIONS,
PRODUCTS AND SURGICAL PROCEDURES, THROUGH 2018 ($ MILLIONS) 28
TABLE 5 NUMBER OF DISCHARGES FROM NONFEDERAL U.S. HOSPITALS FOR
INDIVIDUALS 65 OR OLDER, 2010 (THOUSANDS) 28
TABLE 6 PROJECTED U.S. MARKET FOR PRESCRIPTION ARTHRITIS MEDICATIONS FOR
INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 33
TABLE 7 SELECTED LISTING OF HEART DISEASE MEDICATIONS BY BRAND NAME AND
MANUFACTURER 35
TABLE 8 U.S. MARKET FOR CARDIOVASCULAR DISEASE MEDICATIONS AND SURGERY,
THROUGH 2018 ($ MILLIONS) 38
TABLE 9 PROJECTED U.S. MARKET FOR CARDIOVASCULAR DRUGS AND SURGERY
FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 38
TABLE 10 LEADING CANCER DRUGS, WITH PRODUCT, MANUFACTURER AND
INDICATION, 2012 41
TABLE 11 PROJECTED U.S. MARKET FOR CANCER TREATMENT DRUGS, THROUGH
2018 ($ MILLIONS) 42
TABLE 12 PROJECTED MARKET FOR CANCER DRUGS FOR U.S. ELDERLY PATIENTS,
THROUGH 2018 ($ MILLIONS) 42
TABLE 13 PREVALENCE OF DIABETES IN THE U.S., THROUGH 2018 (CASES IN
MILLIONS) 44
TABLE 14 SULFONYLUREAS 46
TABLE 15 ORAL HYPOGYCEMICS 48
TABLE 16 PROJECTED U.S. MARKET FOR ORAL DIABETES MEDICATIONS AND
MONITORING PRODUCTS, THROUGH 2018 ($ MILLIONS) 49
TABLE 17 PROJECTED U.S. MARKET FOR ORAL DIABETES MEDICATIONS AND
MONITORING PRODUCTS FOR THE ELDERLY, THROUGH 2018 ($ MILLIONS) 50
TABLE 18 PROJECTED U.S. MARKET FOR SENSORY IMPAIRMENT PHARMACEUTICALS,
SURGERY AND PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 50
TABLE 19 ESTIMATED NUMBER OF CASES BY VISION PROBLEM FOR INDIVIDUALS
OVER 40, 2010 52
TABLE 20 PROJECTED GLOBAL MARKET FOR PRODUCTS TO TREAT AMD, THROUGH
2018 ($ MILLIONS) 53
TABLE 21 PROJECTED U.S. MARKET FOR PRODUCTS TO TREAT AMD FOR
INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 53
TABLE 22 PROJECTED COSTS OF CATARACT SURGERY FOR THE U.S. ELDERLY,
THROUGH 2018 ($ MILLIONS) 54
TABLE 23 PROJECTED U.S. ELDERLY MARKET FOR GLAUCOMA PRESCRIPTION
MEDICATIONS, THROUGH 2018 ($ MILLIONS) 55
TABLE 24 PROJECTED U.S. EYEWEAR SALES, THROUGH 2018 ($ MILLIONS) 56
TABLE 25 PROJECTED U.S. MARKET FOR EYEWEAR FOR INDIVIDUALS OVER 65,
THROUGH 2018 ($ MILLIONS) 56
TABLE 26 PROJECTED U.S. MARKET FOR HEARING AID PRODUCTS, THROUGH 2018
($ MILLIONS) 58
TABLE 27 PROJECTED U.S. MARKET FOR HEARING AID PRODUCTS FOR THE ELDERLY,
THROUGH 2018 ($ MILLIONS) 58
TABLE 28 PROJECTED MARKET IN THE U.S. FOR DEMENTIA AND DEPRESSION
MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 59
TABLE 29 COMMON PRESCRIPTION MEDICATIONS FOR ALZHEIMER'S DISEASE, 2013 62
TABLE 30 PROJECTED MARKET IN THE U.S. FOR DEMENTIA MEDICATIONS FOR
INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 63
TABLE 31 PROJECTED U.S. MARKET FOR DEPRESSION MEDICATIONS FOR THE
ELDERLY, THROUGH 2018 ($ MILLIONS) 65
TABLE 32 PROJECTED U.S. MARKET FOR ORTHOPEDIC MEDICATIONS AND
SURGERIES FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 66
TABLE 33 UNCONTROLLABLE AND CONTROLLABLE RISK FACTORS FOR
OSTEOPOROSIS 66
TABLE 34 OSTEOPOROSIS MEDICATIONS BY TYPE 67
TABLE 35 PROJECTED U.S. MARKET FOR OSTEOPOROSIS MEDICATIONS, THROUGH
2018 ($ MILLIONS) 68
TABLE 36 PROJECTED U.S. MARKET FOR OSTEOPOROSIS MEDICATIONS FOR
INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 68
TABLE 37 PROJECTED U.S. COST OF SELECTED ORTHOPEDIC SURGERY, THROUGH
2018 ($ MILLIONS) 69
TABLE 38 PROJECTED U.S. COST OF SELECTED ORTHOPEDIC SURGERY FOR
INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 70
TABLE 39 PROJECTED U.S. MARKET FOR RESPIRATORY MEDICATIONS AND
PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 71
TABLE 40 CURRENT ALLERGY TREATMENTS 73
TABLE 41 PROJECTED MARKET FOR PRESCRIPTION ALLERGY MEDICATIONS IN THE
U.S., THROUGH 2018 ($ MILLIONS) 74
TABLE 42 PROJECTED U.S. MARKET FOR PRESCRIPTION ALLERGY MEDICATIONS FOR
INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 75
TABLE 43 PROJECTED U.S. MARKET FOR ASTHMA MEDICATIONS FOR INDIVIDUALS
OVER 65, THROUGH 2018 ($ MILLIONS) 76
TABLE 44 PROJECTED U.S. MARKET FOR COPD MEDICATIONS FOR INDIVIDUALS
OVER 65, THROUGH 2018 ($ MILLIONS) 77
TABLE 45 CURRENT TREATMENT OPTIONS FOR ASTHMA/COPD IN U.S. 78
TABLE 46 PROJECTED U.S. MARKET FOR HOME OXYGEN AND RESPIRATORY
SUPPLIES FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 80
TABLE 47 MAJOR ASTHMA/COPD DRUGS LOSING PATENT PROTECTION BETWEEN
2008-2021 80
TABLE 48 PROJECTED U.S. MARKET FOR INCONTINENCE MEDICATIONS FOR
INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 82
TABLE 49 SELECTED MEDICATIONS FOR BPH 82
TABLE 50 PROJECTED U.S. MARKET FOR BPH MEDICATIONS FOR INDIVIDUALS OVER
65, THROUGH 2018 ($ MILLIONS) 83
TABLE 51 PROJECTED U.S. MARKET FOR SENIOR HOUSING AND DAY SERVICES FOR
INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 88
TABLE 52 PROJECTED U.S. MARKET FOR HOME REMODELING FOR INDIVIDUALS
OVER 65, THROUGH 2018 ($ MILLIONS) 89
TABLE 53 PROJECTED U.S. MARKET FOR HOME HEALTH SERVICES FOR INDIVIDUALS
OVER 65, THROUGH 2018 ($ MILLIONS) 89
TABLE 54 PROJECTED U.S. MARKET FOR ADULT DAY CARE SERVICES FOR
INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 91
TABLE 55 PROJECTED U.S. MARKET FOR SENIOR ASSISTED LIVING AND SKILLED
NURSING FACILITIES FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 93
TABLE 56 TOP 10 ASSISTED LIVING PROVIDERS IN U.S. BY CAPACITY, 2012 94
TABLE 57 TOP 10 INDEPENDENT LIVING PROVIDERS BY CAPACITY, 2012 95
TABLE 58 TOP FIVE MEMORY CARE LIVING PROVIDERS IN THE U.S., 2012 97
TABLE 59 SELECTED ACQUISITIONS AND MERGERS IN THE ELDERCARE MARKET,
2011 TO 2013 ($ MILLIONS) 104
TABLE 60 PROJECTED U.S. ASSISTIVE TECHNOLOGY MARKET FOR INDIVIDUALS
OVER 65, THROUGH 2018 ($ MILLIONS) 106
TABLE 61 SELECTED MEDICAL/PERSONAL MONITORING AID MANUFACTURERS 109
TABLE 62 PROJECTED U.S. SALES OF MEDICAL/PERSONAL MONITORING AIDS FOR
INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 110
TABLE 63 ACCESS AIDS MANUFACTURERS 112
TABLE 64 SELECTED MANUFACTURERS OF DAILY LIVING AIDS 113
TABLE 65 PROJECTED MARKET FOR DAILY LIVING AIDS FOR SENIORS, THROUGH
2018 ($ MILLIONS) 113
TABLE 66 PROJECTED U.S. MARKET FOR MOBILITY PRODUCTS FOR INDIVIDUALS
OVER 65, THROUGH 2018 ($ MILLIONS) 114
TABLE 67 WHEELCHAIR MANUFACTURERS 115
TABLE 68 SCOOTER MANUFACTURERS 116
TABLE 69 PROJECTED U.S. MARKET FOR AMBULATORY AIDS FOR INDIVIDUALS OVER
65, THROUGH 2018 ($ MILLIONS) 117
TABLE 70 AMBULATORY AID MANUFACTURERS 117
TABLE 71 PROJECTED U.S. MARKET FOR MOTOR VEHICLE MODIFICATIONS FOR
INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 118
TABLE 72 VEHICLE ASSESS CONVERSION KIT MANUFACTURERS 118
TABLE 73 PROJECTED U.S. MARKET FOR NAVIGATION AIDS FOR INDIVIDUALS OVER
65, THROUGH 2018 ($ MILLIONS) 119
TABLE 74 PROJECTED U.S. MARKET FOR OTHER AIDS FOR INDIVIDUALS OVER 65,
THROUGH 2018 ($ MILLIONS) 119
TABLE 75 PROJECTED U.S. ELDERLY MARKET FOR COMMUNICATION AIDS, THROUGH
2018 ($ MILLIONS) 120
TABLE 76 MEDICINES IN DEVELOPMENT FOR SELECTED THERAPEUTIC AREAS, 2012 124
TABLE 77 MAJOR PRODUCT PIPELINES FOR BREAST CANCER 125
TABLE 78 MAJOR PRODUCT PIPELINES FOR COLORECTAL CANCER 126
TABLE 79 MAJOR PRODUCT PIPELINES FOR DIABETES 126
TABLE 80 MAJOR PRODUCT PIPELINES FOR HEART DISEASE/STROKE 128
TABLE 81 MAJOR PRODUCT PIPELINES FOR KIDNEY DISEASE 128
TABLE 82 MAJOR PRODUCT PIPELINES FOR OSTEOARTHRITIS 129
TABLE 83 MAJOR PRODUCT PIPELINES FOR OSTEOPOROSIS 129
TABLE 84 MAJOR PRODUCT PIPELINES FOR PAIN 130
TABLE 85 MAJOR PRODUCT PIPELINES FOR RHEUMATOID ARTHRITIS 131
TABLE 86 MAJOR PRODUCT PIPELINES FOR DEPRESSION 132
TABLE 87 MAJOR PRODUCT PIPELINE FOR DEMENTIA PHARMACEUTICALS 133
TABLE 88 MAJOR PRODUCT PIPELINES FOR ASTHMA 133
TABLE 89 MAJOR PRODUCT PIPELINES FOR COPD 134



LIST OF FIGURES

SUMMARY FIGURE PROJECTED NEEDS OF THE ELDERLY BY TYPE OF NEED, 2013
AND 2018 (%) 9
FIGURE 1 U.S. POPULATION OVER 65 BY RACE, 2010 (%) 20
FIGURE 2 FUTURE BURDEN OF ARTHRITIS FOR THOSE OVER 65 IN THE U.S. BY
GENDER, 2010-2030 ($ MILLIONS) 31
FIGURE 3 ESTIMATED NEW CASES OF CANCER, GLOBALLY, 2008 (%) 39
FIGURE 4 CAUSES OF DEMENTIA IN INDIVIDUALS OVER 65 (%) 60
FIGURE 5 MARKET LEADERS FOR RECONSTRUCTIVE IMPLANT PRODUCTS (%) 70
FIGURE 6 PROJECTED LIFETIME LONG-TERM CARE NEEDS FOR INDIVIDUALS OVER 65
(%) 86
FIGURE 7 PERCENT RANKING OF ASSISTED LIVING PROVIDERS BY CAPACITY IN THE
U.S., 2012 (%) 94
FIGURE 8 PERCENT RANKING OF INDEPENDENT LIVING PROVIDERS BY CAPACITY IN
THE U.S., 2012 (%) 96
FIGURE 9 PROJECTED U.S. MARKET FOR ASSISTIVE TECHNOLOGY FOR INDIVIDUALS
OVER 65, 2013 AND 2018 (%) 107

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cance ...

Analysis of the Global Infectious Disease Diagnostics Market

Analysis of the Global Infectious Disease Diagnostics Market

  • $ 10 000
  • Industry report
  • September 2014
  • by Frost & Sullivan

Molecular Methods Present Significant Opportunities This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast ...

Global Mobile Healthcare Market Devices, Applications, Services Industry Size, Analysis, Market Report, Share, Growth, Trends and Forecast 2014-20

Global Mobile Healthcare Market Devices, Applications, Services Industry Size, Analysis, Market Report, Share, Growth, Trends and Forecast 2014-20

  • $ 7 000
  • Industry report
  • November 2014
  • by Occams

According to WHO approximately 17.3 million people die annually due to CVD and the condition is responsible for 30 percent of the global deaths. Also, 80 percent of CVD deaths take place in low and middle ...


4 Companies

Company Profiles


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.